Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
New medicines: EU opinions and licences, US approvals
CHMP opinions and European Commission licences from the European Medicines Agency, and new medicines approved by the US FDA. Shown in the regulator's own words, with a link to the source; checked every two hours. This is regulatory news, not medical advice, and not sponsored.
November 2026
US · FDA approval, new medicine
Venglustat (Infilbray)
To treat the neurological symptoms of Type 3 Gaucher disease
Approved 18 Nov 2026
US · FDA approval, new medicine
Adrabetadex (Lembaz)
To treat a severe form of Niemann-Pick disease type C
Approved 17 Nov 2026
US · FDA approval, new medicine
Neladalkib (Nelkarmi)
To treat locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer after certain previous therapies
Approved 17 Nov 2026
US · FDA approval, new medicine
Giredestrant (Wilserdly)
To treat adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor 1-mutated locally advanced or metastatic breast cancer whose disease has recurred during or after endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting
Approved 16 Nov 2026
US · FDA approval, new medicine
Gefurulimab-gaks (Klygefa)
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
Approved 13 Nov 2026
US · FDA approval, new medicine
Pimicotinib (Pimjetmi)
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
Approved 13 Nov 2026
US · FDA approval, new medicine
Asundexian (Sunharbo)
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
Approved 9 Nov 2026
October 2026
US · FDA approval, new medicine
Bepirovirsen (Hibsago)
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
Approved 20 Oct 2026
US · FDA approval, new medicine
Pritelivir (Hovilpri)
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
Approved 9 Oct 2026
September 2026
US · FDA approval, new medicine
Tiratricol (Emcitate)
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
Approved 28 Sept 2026
US · FDA approval, new medicine
Tavapadon (Juvmo)
To treat Parkinson’s disease in adults
Approved 25 Sept 2026
US · FDA approval, new medicine
Zilurgisertib (Atebrioz)
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
Approved 25 Sept 2026
US · FDA approval, new medicine
Insulin efsitora alfa-gobe (Onswik)
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):
2 trials are being summarised and will appear here shortly.
Approved 23 Sept 2026
US · FDA approval, new medicine
Lirafugratinib (Lyrfigtu)
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
Approved 23 Sept 2026
US · FDA approval, new medicine
Apitegromab-mstn (Isembyld)
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
Approved 11 Sept 2026
US · FDA approval, new medicine
Floretyrosine F 18 (Pixclara)
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
Approved 11 Sept 2026
US · FDA approval, new medicine
Camizestrant (Etcamah)
To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
Approved 4 Sept 2026
US · FDA approval, new medicine
Zilganersen (Zanvastro)
To treat Alexander disease in pediatric and adult patients
Approved 3 Sept 2026
August 2026
US · FDA approval, new medicine
Rusfertide (Mimrylo)
To treat erythrocytosis in adults with polycythemia vera
Approved 28 Aug 2026
US · FDA approval, new medicine
Brepocitinib (Lisraya)
To treat dermatomyositis in adults
Approved 27 Aug 2026
US · FDA approval, new medicine
Daraxonrasib (Rasonque)
To treat metastatic pancreatic cancer
Approved 26 Aug 2026
US · FDA approval, new medicine
Garetosmab-grts (Pasatru)
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
Approved 19 Aug 2026
US · FDA approval, new medicine
Florquinitau F 18 (Tauklarify)
To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
Approved 13 Aug 2026
US · FDA approval, new medicine
Iberdomide (Zenbexus)
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
Approved 13 Aug 2026
US · FDA approval, new medicine
Oveporexton (Orzeyful)
To treat narcolepsy type 1
Approved 5 Aug 2026
July 2026
US · FDA approval, new medicine
Bevacizumab-vikg (Lytenava)
To treat patients with neovascular (wet) age-related macular degeneration
Approved 24 Jul 2026
US · FDA approval, new medicine
Centanafadine (Simtriyo)
To treat attention-deficit hyperactivity disorder
Approved 24 Jul 2026
US · FDA approval, new medicine
Zidesamtinib (Jideytro)
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
Approved 22 Jul 2026
US · FDA approval, new medicine
Enlicitide decanoate (Lipfendra)
To reduce low-density lipoprotein cholesterol
Approved 15 Jul 2026
US · FDA approval, new medicine
Gedatolisib (Revtorpyk)
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
Approved 14 Jul 2026
US · FDA approval, new medicine
Atacicept-vymj (Trutakna)
To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression
Approved 7 Jul 2026
June 2026
US · FDA approval, new medicine
Veligrotug-vvze (Lumvoa)
To treat thyroid eye disease
Approved 26 Jun 2026
US · FDA approval, new medicine
Tebipenem pivoxil (Utebzi)
To treat complicated urinary tract infections, including pyelonephritis, caused by several susceptible microorganisms in adults who have limited or no alternative oral treatment options
Approved 17 Jun 2026
US · FDA approval, new medicine
Gadoquatrane (Ambelvist)
To detect and visualize lesions with abnormal vascularity, in conjunction with MRI
Approved 12 Jun 2026
May 2026
US · FDA approval, new medicine
Cefepime and zidebactam (Zaynich)
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
Approved 29 May 2026
US · FDA approval, new medicine
Cipepofol (Cypsedo)
To induce general anesthesia in adults undergoing surgery
Approved 29 May 2026
US · FDA approval, new medicine
Ensitrelvir (Xocova)
To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19
Approved 29 May 2026
US · FDA approval, new medicine
Pivekimab sunirine-pvzy (Decnupaz)
To treat adults with blastic plasmacytoid dendritic cell neoplasm
Approved 27 May 2026
US · FDA approval, new medicine
Bulevirtide-gmod (Hepcludex)
To treat chronic hepatitis delta virus infection in adults without cirrhosis or with compensated cirrhosis
Approved 22 May 2026
US · FDA approval, new medicine
Baxdrostat (Baxfendy)
To treat hypertension in combination with other antihypertensive drugs
Approved 15 May 2026
US · FDA approval, new medicine
Sonrotoclax (Beqalzi)
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor
Approved 13 May 2026
US · FDA approval, new medicine
Vepdegestrant (Veppanu)
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Approved 1 May 2026
April 2026
US · FDA approval, new medicine
Doravirine and islatravir (Idvynso)
To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine
Approved 20 Apr 2026
US · FDA approval, new medicine
Orforglipron (Foundayo)
To reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity
Approved 1 Apr 2026
March 2026
US · FDA approval, new medicine
Insulin icodec-abae (Awiqli)
To improve glycemic control in adults with type 2 diabetes mellitus
Approved 26 Mar 2026
US · FDA approval, new medicine
Relacorilant (Lifyorli)
To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab
Approved 25 Mar 2026
US · FDA approval, new medicine
Tividenofusp alfa-eknm (Avlayah)
To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)
Approved 24 Mar 2026
US · FDA approval, new medicine
Icotrokinra (Icotyde)
To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy
Approved 17 Mar 2026
US · FDA approval, new medicine
Linerixibat (Lynavoy)
To treat cholestatic pruritus associated with primary biliary cholangitis
Approved 17 Mar 2026
February 2026
US · FDA approval, new medicine
Navepegritide (Yuviwel)
To increase linear growth in pediatric patients 2 years and older with achondroplasia with open epiphyses
Approved 27 Feb 2026
US · FDA approval, new medicine
Pegzilarginase-nbln (Loargys)
To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
Approved 23 Feb 2026
US · FDA approval, new medicine
Milsaperidone (Bysanti)
To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
Approved 20 Feb 2026
US · FDA approval, new medicine
Difamilast (Adquey)
To treat mild to moderate atopic dermatitis
Approved 12 Feb 2026
January 2026
US · FDA approval, new medicine
Copper histidinate (Zycubo)
To treat Menkes disease
Approved 12 Jan 2026
December 2025
US · FDA approval, new medicine
Tradipitant (Nereus)
To treat vomiting associated with motion
Approved 30 Dec 2025
US · FDA approval, new medicine
Narsoplimab-wuug (Yartemlea)
To treat hematopoietic stem cell transplant-associated thrombotic microangiopathy
Approved 23 Dec 2025
US · FDA approval, new medicine
Aficamten (Myqorzo)
To treat symptomatic obstructive hypertrophic cardiomyopathy
Approved 19 Dec 2025
US · FDA approval, new medicine
Depemokimab-ulaa (Exdensur)
To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapy
Approved 16 Dec 2025
US · FDA approval, new medicine
Etripamil (Cardamyst)
To treat episodes of paroxysmal supraventricular tachycardia
Approved 12 Dec 2025
US · FDA approval, new medicine
Lerodalcibep-liga (Lerochol)
To reduce low-density lipoprotein cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, as an adjunct to diet and exercise
Approved 12 Dec 2025
US · FDA approval, new medicine
Zoliflodacin (Nuzolvence)
To treat uncomplicated urogenital gonorrhea due to Neisseria gonorrhoeae
Approved 12 Dec 2025
November 2025
US · FDA approval, new medicine
Sibeprenlimab-szsi (Voyxact)
To reduce proteinuria in primary immunoglobulin A nephropathy in adults at risk for disease progression
Approved 25 Nov 2025
US · FDA approval, new medicine
Sevabertinib (Hyrnuo)
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
Approved 19 Nov 2025
US · FDA approval, new medicine
Plozasiran (Redemplo)
To reduce triglycerides in adults with familial chylomicronemia syndrome
Approved 18 Nov 2025
US · FDA approval, new medicine
Ziftomenib (Komzifti)
To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options
Approved 13 Nov 2025
US · FDA approval, new medicine
Doxecitine and doxribtimine (Kygevvi)
To treat thymidine kinase 2 deficiency in patients who start to show symptoms when they are 12 years old or younger
Approved 3 Nov 2025
October 2025
US · FDA approval, new medicine
Elinzanetant (Lynkuet)
To treat moderate-to-severe vasomotor symptoms due to menopause
Approved 24 Oct 2025